Psoriasis Treatment in 2026: From Topicals to the New Oral Biologic

Psoriasis treatment in 2026 looks nothing like it did a decade ago. The approval of ICOTYDE, the first oral biologic, has added yet another rung to a treatment ladder that now spans from over-the-counter moisturizers to targeted injectable therapies capable of clearing skin completely. With so many options available, the challenge for patients and providers is no longer a lack of treatments — it is choosing the right one.

This guide walks through every major psoriasis treatment available in 2026, organized by the treatment ladder from mildest to most aggressive.

Understanding Psoriasis

Psoriasis is a chronic autoimmune condition that causes the immune system to attack skin cells, accelerating their growth cycle from the normal 28–30 days to just 3–4 days. This rapid turnover causes cells to pile up on the skin surface, forming the thick, silvery-white, scaly plaques characteristic of the disease.

Types of Psoriasis

• Plaque psoriasis — the most common form (~80–90% of cases), presenting as raised, red patches with silvery scales
• Guttate psoriasis — small, drop-shaped lesions, often triggered by streptococcal infection
• Inverse psoriasis — smooth, red patches in skin folds (armpits, groin, under breasts)
• Pustular psoriasis — white, pus-filled blisters surrounded by red skin
• Erythrodermic psoriasis — widespread redness covering most of the body; a medical emergency

Treatment decisions depend on the type of psoriasis, severity (measured by body surface area and quality-of-life impact), location, comorbidities, and patient preference.

The 2026 Psoriasis Treatment Ladder

Level	Treatment Class	Best For	Examples
1	Topical therapies	Mild psoriasis, localized plaques	Corticosteroids, vitamin D analogs, Vtama, Zoryve
2	Phototherapy	Moderate psoriasis, widespread thin plaques	Narrowband UVB, excimer laser
3	Oral systemics (traditional)	Moderate-severe psoriasis	Methotrexate, acitretin, cyclosporine
4	Oral targeted therapies	Moderate-severe, injection-averse	Sotyktu (deucravacitinib), apremilast, ICOTYDE
5	Injectable biologics	Moderate-severe, maximum efficacy	Skyrizi, Tremfya, Cosentyx, Taltz, Humira

Level 1: Topical Therapies

Topical treatments are the first line for mild psoriasis and for localized plaques regardless of overall disease severity. They are applied directly to the skin and work locally with minimal systemic absorption.

Topical Corticosteroids

Still the backbone of psoriasis treatment. Available in a range of potencies from mild (hydrocortisone) to super-potent (clobetasol). Effective for rapid plaque reduction, but long-term use carries risks of skin thinning, striae, and rebound flares. Best used in courses with breaks rather than continuously.

Vitamin D Analogs

Calcipotriene (Dovonex) and calcitriol slow skin cell growth and flatten plaques. Often used in combination with topical steroids (Enstilar, Taclonex) for enhanced efficacy. Well-tolerated for long-term use on body sites, though can cause irritation on facial skin.

Tapinarof (Vtama)

An aryl hydrocarbon receptor (AhR) agonist approved for plaque psoriasis in adults. Applied once daily. AhR activation downregulates Th17 inflammatory pathways — the same pathways targeted by the most effective biologics. Vtama is non-steroidal and has shown sustained benefit even after discontinuation (a "remittive effect"). The most common side effect is folliculitis.

Roflumilast Cream (Zoryve)

A topical PDE4 inhibitor approved for plaque psoriasis. Applied once daily. Effective for body plaques and also specifically approved for intertriginous (skin fold) psoriasis. Well-tolerated with low rates of application site reactions.

Level 2: Phototherapy

Phototherapy uses controlled ultraviolet light to slow skin cell turnover and reduce inflammation.

• Narrowband UVB (NB-UVB): The most commonly used form, administered in-office 2–3 times per week. Effective for widespread thin plaques, guttate psoriasis, and cases that do not respond adequately to topicals alone.
• Excimer laser (308 nm): Targeted phototherapy for individual plaques. Useful for localized disease that is resistant to topicals without treating uninvolved skin.
• Home phototherapy units: FDA-cleared NB-UVB devices are available for home use with a prescription, improving access for patients who cannot attend frequent office visits.

Phototherapy is safe and effective but requires consistent attendance and can be time-consuming. It is less practical for patients with limited schedules or geographic access barriers.

Level 3: Traditional Oral Systemics

For moderate-to-severe psoriasis that does not respond to topicals and phototherapy, traditional systemic medications offer broader immunosuppression.

Methotrexate

An anti-metabolite taken once weekly (oral or injectable). It has been used for psoriasis for over 50 years and remains effective for plaque and psoriatic arthritis. Requires routine blood monitoring for liver and bone marrow toxicity. Contraindicated in pregnancy and heavy alcohol use.

Acitretin (Soriatane)

An oral retinoid that normalizes skin cell growth. Particularly useful for pustular and erythrodermic psoriasis. Side effects include dryness, lipid elevation, and severe teratogenicity (pregnancy must be avoided for 3 years after discontinuation).

Cyclosporine

A calcineurin inhibitor that rapidly controls severe flares. Effective but limited to short-term use (typically 3–6 months) due to nephrotoxicity and hypertension risk. Useful as a "bridge" while transitioning to a biologic.

Level 4: Oral Targeted Therapies

This category has expanded dramatically and now includes three distinct drug classes, including the groundbreaking ICOTYDE.

Apremilast (Otezla)

An oral PDE4 inhibitor that reduces multiple inflammatory cytokines. Modestly effective for mild-to-moderate psoriasis (PASI 75 rates around 30–35%). Well-tolerated but GI side effects (nausea, diarrhea) are common initially. Available as a generic, making it one of the more affordable options.

Deucravacitinib (Sotyktu)

An oral TYK2 inhibitor approved in 2022 for moderate-to-severe plaque psoriasis. More effective than apremilast (PASI 75 rates around 55–60%) with a good safety profile. Taken once daily without food restrictions. Does not require routine blood monitoring. Represents the first oral psoriasis treatment that approached biologic-level efficacy, though injectable IL-23 and IL-17 inhibitors still outperform it.

ICOTYDE (Icotrokinra) — NEW in 2026

The first oral biologic for psoriasis. ICOTYDE is an oral IL-23 receptor antagonist peptide that delivers biologic-class efficacy in pill form. With PASI 90 rates of approximately 65% at week 16, ICOTYDE significantly outperforms both apremilast and Sotyktu and approaches the efficacy of injectable IL-23 inhibitors.

ICOTYDE fills the gap that has long existed between oral treatments with modest efficacy and injectable biologics with excellent efficacy. For patients who refuse or cannot use injections, ICOTYDE is now the clear first choice among oral options. Read our full ICOTYDE guide.

Level 5: Injectable Biologics

Biologics remain the gold standard for moderate-to-severe psoriasis when maximum skin clearance is the goal.

IL-23 Inhibitors (Top Tier)

• Skyrizi (risankizumab): The current leader. PASI 90 rates of ~72–75%. Dosed every 12 weeks after loading. Excellent long-term safety data.
• Tremfya (guselkumab): PASI 90 rates of ~70%. Dosed every 8 weeks. Strong efficacy with a clean safety profile.
• Ilumya (tildrakizumab): Slightly lower efficacy than Skyrizi and Tremfya but still effective. Dosed every 12 weeks.

IL-17 Inhibitors

• Cosentyx (secukinumab): PASI 90 rates ~65%. Dosed monthly after loading.
• Taltz (ixekizumab): PASI 90 rates ~68–72%. Rapid onset of action. Dosed every 4 weeks after loading.
• Bimzelx (bimekizumab): Dual IL-17A/F inhibitor. PASI 90 rates ~85%. Among the most effective biologics available but higher rates of oral candidiasis.

TNF Inhibitors (Older Generation)

• Humira (adalimumab): PASI 90 rates ~40%. Now largely superseded by IL-23 and IL-17 inhibitors but still used, particularly as biosimilars reduce cost.
• Enbrel (etanercept): Lower efficacy. Rarely a first-line biologic for psoriasis in 2026.

How to Choose the Right Treatment

The right psoriasis treatment depends on several factors:

• Severity: Mild (topicals) → Moderate (phototherapy, oral targeted) → Severe (biologics)
• Injection tolerance: If needle-averse, ICOTYDE is now the strongest non-injection option
• Psoriatic arthritis: If joint involvement is present, biologics (especially IL-17 and TNF inhibitors) address both skin and joints
• Insurance and cost: Generic methotrexate and apremilast are the most affordable; biologics typically require manufacturer copay assistance
• Comorbidities: Liver disease limits methotrexate; kidney disease limits cyclosporine; infection history affects biologic choice
• Speed of response: Cyclosporine and IL-17 inhibitors work fastest; IL-23 inhibitors take longer to peak but offer durable responses

The Bottom Line

Psoriasis treatment in 2026 offers more options and better outcomes than at any point in history. The arrival of ICOTYDE means that patients no longer have to choose between pills with modest efficacy and injections with excellent efficacy. At the same time, newer topicals like Vtama and Zoryve have expanded the options for mild disease, and the injectable biologics continue to push clearance rates higher.

The key is working with a dermatologist to identify where you sit on the treatment ladder and what matters most to you — whether that is convenience, efficacy, cost, or safety. Use the MedSwitcher comparison tool to compare psoriasis medications head-to-head.

Sources

1. American Academy of Dermatology (AAD) Psoriasis Treatment Guidelines, 2024 update.
2. Prescribing information for all referenced medications.
3. VIVID (ICOTYDE), POETYK (Sotyktu), and BE VIVID (Bimzelx) Phase 3 trial data.
4. National Psoriasis Foundation treatment resources.
5. MedSwitcher editorial analysis, April 2026.